What is durvalumab (durvalumab)? What class of drugs does it belong to and what are its clinical applications?

Durvalumab (trade name: Imfinzi) is an immune checkpoint inhibitor, a monoclonal antibody drug that mainly works by targeting PD-L1 (programmed death ligand 1). PD-L1 is a protein expressed on the surface of many tumor cells. After binding to the PD-1 receptor on the surface of T cells, it inhibits the immune activity of T cells, allowing tumor cells to evade immune surveillance. By blocking the interaction between PD-L1 and PD-1, durvalumab relieves the suppression of the immune system, thereby enhancing the anti-tumor activity of T cells and promoting the immune system to recognize and eliminate tumor cells.

Durvalumab belongs to the " immune checkpoint inhibitors" class of immunotherapy drugs. Immune checkpoint inhibitors are a class of drugs that treat cancer by restoring or enhancing the function of a patient's immune system. They have significant potential in cancer treatment, especially in patients with certain refractory or advanced cancers.

In terms of clinical application, durvalumab has been approved for the treatment of various cancers. The most common indications include:

1.Non-small cell lung cancer (NSCLC): used to treat patients with advanced or metastatic non-small cell lung cancer who have previously received chemotherapy, especially those with high PD-L1 expression.

2.Local advanced or metastatic urothelial cancer: Durvalumab is also used to treat these cancers, particularly in those patients who have failed chemotherapy.

3.Small cell lung cancer: As part of combination therapy, durvalumab is also used to treat small cell lung cancer, especially in maintenance treatment after chemotherapy.

Overall, durvalumab has shown good results in the treatment of various cancers through its immunomodulatory effect and is one of the important advances in the field of cancer immunotherapy. As research progresses, durvalumab may be further used in the treatment of more types of tumors.